New Merger Advances CRPS Treatment
Werewolf and Ambros Therapeutics Merge in $150 Million Deal to Advance CRPS Treatment
Key Points
The neridronate-focused CRPS-RISE Phase 3 program is designed as a randomized, triple-blind trial enrolling about 270 patients, with the primary endpoint centered on changes in pain intensity through Week 12.
The merger is expected to close in the first quarter of 2027, subject to customary closing conditions and shareholder approvals.
The concurrent $150 million private placement is being co-led by RA Capital Management and Janus Henderson Investors, with participation from additional healthcare-focused investors, and the financing was oversubscribed.
Ownership terms are subject to adjustment based on Werewolf’s net cash at closing, adding a potential variance to the post-merger ownership split.
The merged company will be headquartered in San Diego and will operate as Ambros Therapeutics, trading under the Nasdaq ticker AMBX.
Werewolf Therapeutics and Ambros Therapeutics announced a merger deal that will create a new company focused on treating Complex Regional Pain Syndrome Type 1 (CRPS-1). TipRanks reported the combined company will trade on Nasdaq as AMBX and will be backed by a $150 million private investment. Werewolf shareholders saw their stock surge 120% following the announcement Yahoo Finance.
The deal values Ambros at roughly $500 million and Werewolf at about $47.5 million before the new investment. TradingView noted the private placement was oversubscribed, with co-leads from RA Capital Management and Janus Henderson Investors. The merger is expected to close in the first quarter of 2027.
The Merger Terms and Ownership Split
In the all-stock merger, Ambros will be the surviving company, with TradingView reporting that pre-merger Ambros holders will own roughly 71.7% of the combined entity. Werewolf shareholders will hold about 6.8%, while new investors from the private placement will own approximately 21.5%. The headquarters will be in San Diego.
Ownership percentages may shift slightly based on Werewolf's net cash position at closing. Ambros leadership will run the merged company. The deal includes customary closing conditions and requires shareholder approval from both companies before it can proceed.
The $150 Million Financing Behind the Deal
The concurrent private placement is being led by RA Capital Management and Janus Henderson Investors, with participation from other healthcare-focused investors. TradingView reported the round was oversubscribed, meaning more investors wanted in than available shares. This financing gives the merged company runway through the first half of 2029.
The timing of the investment aligns with the company's clinical plans. The cash will support the Phase 3 trial for neridronate. This ensures the combined company has funding to complete key trial milestones without needing to raise more money soon.
Neridronate's Path to Market in CRPS-1
Neridronate is designed to treat Complex Regional Pain Syndrome Type 1, a painful condition that affects about 600,000 patients globally. TipRanks reported the drug already has FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations. It is already approved and used in Italy for CRPS and other conditions.
The Phase 3 trial, called CRPS-RISE, will enroll about 270 patients in a randomized, triple-blind study. The primary goal is to measure changes in pain intensity over 12 weeks. TipRanks indicated topline results are expected in 2028, with an NDA submission to follow.
What This Merger Means for the Companies
For Werewolf, the merger provides a path forward after facing challenges as a standalone company. Shareholders received an immediate 120% stock price boost as markets reacted positively to the deal. Yahoo Finance noted the partnership combines Werewolf's assets with Ambros's clinical program and investor backing.
For Ambros, the merger brings capital and scale to support the neridronate program through late-stage development. The combined company trades as a single public entity, reducing overhead and streamlining decision-making. Both companies' investors benefit from a clearer path to potential FDA approval and commercialization.
Sentiment
Mostly PositivePublishers
11
Articles
29
Reach
40
